CAGE Bio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, CAGE Bio sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).
CAGE Bio: 8 sponsored US clinical trials, 1 recruiting.
CAGE Bio sponsors 8 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 7 completed. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Atopic Dermatitis (AD), with 1 trials.
Upper-quartile sponsor footprint
CAGE Bio sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
8 total, page 1 of 1
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
NCT06810050
A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis
NCT06923228
An Open-label Study Evaluating the Effectiveness of CGB-400 Topical Gel for Fungal Infection
NCT05202366
CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea
NCT04886739
Clinical Evaluation of the Residual Antimicrobial Activity
NCT04495920
CGB-400 for the Reduction of Facial Redness and Bumps and Blemishes
NCT04508205
CGB-400 for the Reduction of Facial Redness
NCT04508660
50 Human Subject Repeat Insult Patch Test
NCT04498676
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the CAGE Bio pipeline
1 recruiting of 8 indexed (13% open); 7 completed (88%).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Atopic Dermatitis (AD) (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
CAGE Bio: open-pipeline peers nationwide
Peers matched on 8 registered trials and 13% open enrollment, not the therapeutic-area sidebar.
CAGE Bio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 8 trials (± recruiting share)
- AB Science · 8 trials · 25% recruiting
- Abbott Point of Care · 8 trials · 25% recruiting
- Abeona Therapeutics · 8 trials · 0% recruiting
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 8 trials · 38% recruiting
Sponsors near 13% open enrollment (± trial volume)
- Addario Lung Cancer Medical Institute · 13% recruiting · 8 trials
- American University · 13% recruiting · 16 trials
- Annexon · 13% recruiting · 8 trials
- Ansun Biopharma · 13% recruiting · 8 trials
Related
What to do with this CAGE Bio page
8 registered trials is a research-attention snapshot, not an endorsement of CAGE Bio or any single study.
- 1 of CAGE Bio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Atopic Dermatitis (AD) is the condition CAGE Bio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Atopic Dermatitis (AD) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. CAGE Bio pipeline card: 8 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.